Loading
companiesCompany
Teva Pharmaceuticals
Teva is the world's largest generic medicines company; its branded oncology products include omacetaxine (Synribo) for resistant chronic myeloid leukaemia, arsenic trioxide (Trisenox), bendamustine (Bendeka) and the G-CSF products Granix and Lonquex.
Also called: CephalonActavis Inc.ActavisTeva Branded Pharmaceutical Products R&D, Inc.Barr LaboratoriesWatson Pharmaceuticals
Overview
Teva Pharmaceuticals, based in Tel Aviv and listed as TEVA, is the world's largest generic medicines company; its branded oncology products include omacetaxine, sold as Synribo, for resistant chronic myeloid leukaemia, arsenic trioxide as Trisenox, bendamustine as Bendeka and the G-CSF products Granix and Lonquex. It acquired Cephalon in 2011, gaining Trisenox, Treanda and Synribo, and markets tbo-filgrastim as Granix in the United States and lipegfilgrastim as Lonquex in Europe, alongside the largest generic oncology injectables portfolio worldwide. OnCo links it to filgrastim, lipegfilgrastim and omacetaxine. Whether the largest generic injectables maker can keep supply steady through the recurring shortages that hit chemotherapy is the question its scale invites. Each product has its own page.
Headquarters
Tel Aviv, IL
Scorecard
All companies#47of 1244 companies, score 74
- approved products +30
- targets +4
- modalities +4
- regions +6
- registry trials +30
5 approved, 0 in phase 3, 0 earlier, 2 targets, 1,676 registry studies. Formula on the scorecards page.
Type
Large pharma · TEVA
Stage
Public
Website
ApprovedInorganic arsenical (differentiation agent)
Arsenic trioxide · Trisenox
An ancient poison turned cure: with retinoic acid it cures more than 95% of acute promyelocytic leukaemia without conventional chemotherapy.
ApprovedRecombinant erythropoietin (erythropoiesis-stimulating agent)
Epoetin theta · Eporatio / Biopoin
Epoetin theta is a made-to-order version of erythropoietin, the hormone that tells the marrow to make red blood cells. It is used to treat the anaemia of chemotherapy in people with non-myeloid cancers, sparing some transfusions.
ApprovedRecombinant granulocyte colony-stimulating factor
Filgrastim (G-CSF) · Neupogen
Filgrastim (Neupogen and its biosimilars) is a daily injection that speeds the recovery of infection-fighting white cells after chemotherapy, lets doctors give chemotherapy on schedule and mobilises stem cells for transplant.
ApprovedGlycopegylated recombinant G-CSF
Lipegfilgrastim · Lonquex
Lipegfilgrastim (Lonquex) is a once-per-chemotherapy-cycle white cell booster used in Europe, similar to pegfilgrastim, for adults and children from two years old.
ApprovedProtein synthesis inhibitor (cephalotaxine ester)
Omacetaxine mepesuccinate · Synribo
Omacetaxine (Synribo) is a twice-daily injection under the skin for chronic myeloid leukaemia that has stopped responding to at least two tyrosine kinase inhibitor pills.
Similar pages
- CompanySandoz
Shares Oral solid dose manufacturing (tablets and capsules), Filgrastim (G-CSF), Generic sterile injectables (the 2023 platinum shortage).
- CompanyAmneal Pharmaceuticals
Shares Oral solid dose manufacturing (tablets and capsules), Generic sterile injectables (the 2023 platinum shortage).
- CompanyDr. Reddy's Laboratories
Shares Oral solid dose manufacturing (tablets and capsules), Small-molecule API synthesis, Generic sterile injectables (the 2023 platinum shortage).
- TreatmentPegfilgrastim
Shares Lipegfilgrastim, XM22-03, Efficacy and safety of lipegfilgrastim versus pegfilgrastim in breast cancer patients receiving doxorubicin and docetaxel (XM22-03), Filgrastim (G-CSF).
- CompanyCipla
Shares Oral solid dose manufacturing (tablets and capsules), Small-molecule API synthesis.
- CompanyIntas Pharmaceuticals (Accord Healthcare)
Shares Oral solid dose manufacturing (tablets and capsules), Generic sterile injectables (the 2023 platinum shortage).
- TechnologyGMP, inspections, Form 483s and warning letters
Shares Oral solid dose manufacturing (tablets and capsules), Small-molecule API synthesis, Generic sterile injectables (the 2023 platinum shortage).
- CompanyViatris
Shares Oral solid dose manufacturing (tablets and capsules), Generic sterile injectables (the 2023 platinum shortage).
technologies
drugs
ApprovedInorganic arsenical (differentiation agent)
Arsenic trioxide · Trisenox
ApprovedRecombinant erythropoietin (erythropoiesis-stimulating agent)
Epoetin theta · Eporatio / Biopoin
ApprovedRecombinant granulocyte colony-stimulating factor
Filgrastim (G-CSF) · Neupogen
ApprovedGlycopegylated recombinant G-CSF
Lipegfilgrastim · Lonquex
ApprovedProtein synthesis inhibitor (cephalotaxine ester)
Omacetaxine mepesuccinate · Synribo